Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

NCT06538896 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer
Bone Metastases

Interventions

DRUG: Tislelizumab + Nab-Paclitaxel
OTHER: Rankl inhibitor

Sponsor

Zhejiang Cancer Hospital